Baillie Gifford & Co
EVH icon

Baillie Gifford & Co’s Evolent Health EVH Stock Holding History

Baillie Gifford & Co’s Portfolio EVH Stock Details EVH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,084,001
Closed -$7.79M – 227
2019
Q3 		$7.79M Buy
1,084,001
+11,584
+1% +$83.1K 0.01% 185
2019
Q2 		$8.53M Sell
1,072,417
-967
-0.1% -$11.4K 0.01% 195
2019
Q1 		$13.5M Buy
1,073,384
+42,631
+4% +$675K 0.01% 181
2018
Q4 		$20.6M Buy
1,030,753
+27,604
+3% +$639K 0.03% 157
2018
Q3 		$28.5M Buy
1,003,149
+134,935
+16% +$3.22M 0.03% 136
2018
Q2 		$18.3M Buy
+868,214
New +$16.4M 0.02% 151

Other funds holding EVH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

Baillie Gifford & Co's EVH Position: Q4 2019 in Review

Baillie Gifford & Co sold out of Evolent Health (EVH) in Q4 2019, closing a stake of 1,084,001 shares — an estimated $7.79M sold.

Baillie Gifford & Co first reported a position in EVH in Q2 2018 and held it in 6 quarters. The position peaked at $28.5M in Q3 2018. 167 funds tracked by Wall St. Rank hold EVH as of Q4 2019.

  • Baillie Gifford & Co reported no remaining Evolent Health position as of Q4 2019 after selling out during the quarter.
  • Baillie Gifford & Co sold 1,084,001 Evolent Health shares in Q4 2019, an estimated $7.79M.
  • Baillie Gifford & Co first reported a position in Evolent Health in Q2 2018 and held it in 6 quarters.
  • Baillie Gifford & Co's Evolent Health position peaked at $28.5M in Q3 2018.
  • 167 funds tracked by Wall St. Rank held Evolent Health as of Q4 2019.

Based on Baillie Gifford & Co's 13F filing for Q4 2019, filed 10 Feb 2020.